ABBV
Price
$220.61
Change
+$2.07 (+0.95%)
Updated
Sep 26 closing price
Capitalization
389.72B
27 days until earnings call
AZNCF
Price
$146.16
Change
-$3.59 (-2.40%)
Updated
Sep 26 closing price
Capitalization
228.48B
Interact to see
Advertisement

ABBV vs AZNCF

Header iconABBV vs AZNCF Comparison
Open Charts ABBV vs AZNCFBanner chart's image
ABBVIE
Price$220.61
Change+$2.07 (+0.95%)
Volume$4.19M
Capitalization389.72B
AstraZeneca
Price$146.16
Change-$3.59 (-2.40%)
Volume$944
Capitalization228.48B
ABBV vs AZNCF Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AZNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. AZNCF commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and AZNCF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (ABBV: $220.61 vs. AZNCF: $146.16)
Brand notoriety: ABBV: Notable vs. AZNCF: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 85% vs. AZNCF: 21%
Market capitalization -- ABBV: $389.72B vs. AZNCF: $228.48B
ABBV [@Pharmaceuticals: Major] is valued at $389.72B. AZNCF’s [@Pharmaceuticals: Major] market capitalization is $228.48B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $649.52B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $87.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileAZNCF’s FA Score has 1 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • AZNCF’s FA Score: 1 green, 4 red.
According to our system of comparison, ABBV is a better buy in the long-term than AZNCF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 3 TA indicator(s) are bullish while AZNCF’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 3 bullish, 5 bearish.
  • AZNCF’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than AZNCF.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -0.84% price change this week, while AZNCF (@Pharmaceuticals: Major) price change was -5.32% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.20%. For the same industry, the average monthly price growth was -0.44%, and the average quarterly price growth was +12.50%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.20% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($390B) has a higher market cap than AZNCF($228B). ABBV has higher P/E ratio than AZNCF: ABBV (105.05) vs AZNCF (27.53). ABBV YTD gains are higher at: 27.569 vs. AZNCF (12.431). AZNCF has higher annual earnings (EBITDA): 16.8B vs. ABBV (14.2B). AZNCF has more cash in the bank: 7.11B vs. ABBV (6.47B). AZNCF has less debt than ABBV: AZNCF (32.8B) vs ABBV (70.5B). ABBV (58.3B) and AZNCF (56.5B) have equivalent revenues.
ABBVAZNCFABBV / AZNCF
Capitalization390B228B171%
EBITDA14.2B16.8B85%
Gain YTD27.56912.431222%
P/E Ratio105.0527.53382%
Revenue58.3B56.5B103%
Total Cash6.47B7.11B91%
Total Debt70.5B32.8B215%
FUNDAMENTALS RATINGS
ABBV vs AZNCF: Fundamental Ratings
ABBV
AZNCF
OUTLOOK RATING
1..100
1584
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
858
SMR RATING
1..100
1346
PRICE GROWTH RATING
1..100
2059
P/E GROWTH RATING
1..100
1280
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AZNCF's Valuation (21) in the null industry is significantly better than the same rating for ABBV (89) in the Pharmaceuticals Major industry. This means that AZNCF’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZNCF (58) in the null industry. This means that ABBV’s stock grew somewhat faster than AZNCF’s over the last 12 months.

ABBV's SMR Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZNCF (46) in the null industry. This means that ABBV’s stock grew somewhat faster than AZNCF’s over the last 12 months.

ABBV's Price Growth Rating (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZNCF (59) in the null industry. This means that ABBV’s stock grew somewhat faster than AZNCF’s over the last 12 months.

ABBV's P/E Growth Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for AZNCF (80) in the null industry. This means that ABBV’s stock grew significantly faster than AZNCF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVAZNCF
RSI
ODDS (%)
Bearish Trend 3 days ago
40%
Bearish Trend 7 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
48%
Bullish Trend 3 days ago
69%
Momentum
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
55%
MACD
ODDS (%)
Bearish Trend 3 days ago
42%
Bearish Trend 3 days ago
63%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
44%
Bearish Trend 3 days ago
55%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
54%
Advances
ODDS (%)
Bullish Trend 6 days ago
58%
Bullish Trend 7 days ago
66%
Declines
ODDS (%)
Bearish Trend 4 days ago
44%
Bearish Trend 5 days ago
49%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
39%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AZNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PMHG51.150.10
+0.20%
Prime Meridian Holding Co.
PBNNF0.25N/A
N/A
PT Bank Negara Indonesia TBK
XTEPY74.51N/A
N/A
Xtep International Holdings Ltd.
PLMUF11.02N/A
N/A
Plum Acquisition Corp. III
GTHP0.24-0.02
-5.88%
Guided Therapeutics, Inc.

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with AMGN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
+0.95%
AMGN - ABBV
53%
Loosely correlated
+0.66%
PFE - ABBV
48%
Loosely correlated
+0.68%
MRK - ABBV
47%
Loosely correlated
+1.24%
BIIB - ABBV
43%
Loosely correlated
+1.25%
NVS - ABBV
39%
Loosely correlated
+1.16%
More

AZNCF and

Correlation & Price change

A.I.dvisor tells us that AZNCF and BAYRY have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AZNCF and BAYRY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZNCF
1D Price
Change %
AZNCF100%
-2.40%
BAYRY - AZNCF
20%
Poorly correlated
+0.25%
AZN - AZNCF
16%
Poorly correlated
+0.31%
ABBV - AZNCF
9%
Poorly correlated
+0.95%
ALPMY - AZNCF
9%
Poorly correlated
-0.16%
ALPMF - AZNCF
7%
Poorly correlated
+0.91%
More